Nothing Special   »   [go: up one dir, main page]

AU2002214854A1 - Lipid formulations for target delivery - Google Patents

Lipid formulations for target delivery

Info

Publication number
AU2002214854A1
AU2002214854A1 AU2002214854A AU1485402A AU2002214854A1 AU 2002214854 A1 AU2002214854 A1 AU 2002214854A1 AU 2002214854 A AU2002214854 A AU 2002214854A AU 1485402 A AU1485402 A AU 1485402A AU 2002214854 A1 AU2002214854 A1 AU 2002214854A1
Authority
AU
Australia
Prior art keywords
target delivery
lipid formulations
lipid
active agent
systemic delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002214854A
Inventor
Pieter R. Cullis
David B. Fenske
Ian Maclachlan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Inex Pharmaceuticals Corp
Original Assignee
University of British Columbia
Inex Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia, Inex Pharmaceuticals Corp filed Critical University of British Columbia
Publication of AU2002214854A1 publication Critical patent/AU2002214854A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides lipid-based systemic delivery vehicles and method for selectively targeting an active agent to a specific tissue site. The methods include designing a lipid-based systemic delivery vehicle having a plurality of constitutent parts, and thereafter varying the amounts of each of the plurality of constituent parts to impart tissue selectivity. After tissue selectivity is imparted it is possible to selectively target an active agent to a specific tissue site.
AU2002214854A 2000-10-25 2001-10-25 Lipid formulations for target delivery Abandoned AU2002214854A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24318500P 2000-10-25 2000-10-25
US60/243,185 2000-10-25
PCT/CA2001/001513 WO2002034236A2 (en) 2000-10-25 2001-10-25 Lipid formulations for target delivery

Publications (1)

Publication Number Publication Date
AU2002214854A1 true AU2002214854A1 (en) 2002-05-06

Family

ID=22917671

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002214854A Abandoned AU2002214854A1 (en) 2000-10-25 2001-10-25 Lipid formulations for target delivery

Country Status (7)

Country Link
EP (1) EP1328254B1 (en)
JP (1) JP2004511572A (en)
AT (1) ATE354350T1 (en)
AU (1) AU2002214854A1 (en)
CA (1) CA2426244A1 (en)
DE (1) DE60126801T2 (en)
WO (1) WO2002034236A2 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE485031T1 (en) 2002-06-28 2010-11-15 Protiva Biotherapeutics Inc METHOD AND DEVICE FOR PRODUCING LIPOSOMES
SG190613A1 (en) * 2003-07-16 2013-06-28 Protiva Biotherapeutics Inc Lipid encapsulated interfering rna
WO2005105152A2 (en) 2004-05-05 2005-11-10 Atugen Ag Lipids, lipid complexes and use thereof
WO2006069782A2 (en) * 2004-12-27 2006-07-06 Silence Therapeutics Ag. Lipid complexes coated with peg and their use
WO2005121348A1 (en) 2004-06-07 2005-12-22 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
JP4764426B2 (en) 2004-06-07 2011-09-07 プロチバ バイオセラピューティクス インコーポレイティッド Cationic lipids and methods of use
WO2006002538A1 (en) * 2004-07-02 2006-01-12 Protiva Biotherapeutics, Inc. Immunostimulatory sirna molecules and uses therefor
WO2006053430A1 (en) * 2004-11-17 2006-05-26 Protiva Biotherapeutics, Inc. Sirna silencing of apolipoprotein b
AU2005316213C1 (en) * 2004-12-16 2011-08-25 Protech Research Pty Ltd Transfer of molecules
EP1824453A4 (en) * 2004-12-16 2010-08-18 Protech Res Pty Ltd Transfer of molecules
TW200800235A (en) * 2005-10-18 2008-01-01 Otsuka Pharma Co Ltd Carrier composition for nucleic acid transport
EP1948674A4 (en) 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc Modified sirna molecules and uses thereof
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
EP2546337A1 (en) 2006-07-21 2013-01-16 Silence Therapeutics AG Means for inhibiting the expression of protein kinase 3
US8193246B2 (en) 2006-12-19 2012-06-05 Marina Biotech, Inc. Lipids and lipid assemblies comprising transfection enhancer elements
US8592382B2 (en) * 2007-05-25 2013-11-26 The University Of British Columbia Formulations for the oral administration of therapeutic agents and related methods
US8765172B2 (en) * 2007-12-10 2014-07-01 Epitarget As Acoustically sensitive drug delivery particles comprising non-lamellar forming lipids
ES2638448T3 (en) 2008-04-15 2017-10-20 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid administration
CN102245590B (en) 2008-10-09 2014-03-19 泰米拉制药公司 Improved amino lipids and methods for the delivery of nucleic acids
JP2012507565A (en) 2008-10-30 2012-03-29 グオ・ペイシュエン Viral DNA packaging motor protein connector biosensor embedded in membrane for DNA sequencing and other applications
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
JP5766188B2 (en) 2009-07-01 2015-08-19 プロチバ バイオセラピューティクス インコーポレイティッド Lipid formulations for delivering therapeutic agents to solid tumors
WO2011000108A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein b
WO2011050457A1 (en) 2009-10-26 2011-05-05 The University Of British Columbia Stabilized formulation for oral administration of therapeutic agents and related methods
CA3077990A1 (en) 2009-12-01 2011-06-09 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
WO2012075040A2 (en) 2010-11-30 2012-06-07 Shire Human Genetic Therapies, Inc. mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
KR102128248B1 (en) 2011-06-08 2020-07-01 샤이어 휴먼 지네틱 테라피즈 인크. Lipid nanoparticle compositions and methods for mrna delivery
US20150267192A1 (en) 2012-06-08 2015-09-24 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
ES2873600T3 (en) 2013-02-05 2021-11-03 1Globe Health Inst Llc Biodegradable and clinically compatible nanoparticles as drug delivery vehicles.
ES2689523T3 (en) 2013-03-14 2018-11-14 Translate Bio, Inc. MRNA-based compositions of the CFTR gene and related methods and uses
ES2708561T3 (en) 2013-03-14 2019-04-10 Translate Bio Inc Methods for the purification of messenger RNA
JP2016175841A (en) * 2013-08-02 2016-10-06 三郎 斎藤 Liposome, and vaccine composition that induces cytotoxic t lymphocyte activity
EA034103B1 (en) 2013-10-22 2019-12-27 Транслейт Био, Инк. METHOD OF TREATING PHENYLKETONURIA USING mRNA
EA201690590A1 (en) 2013-10-22 2016-12-30 Шир Хьюман Дженетик Терапис, Инк. THERAPY OF INSUFFICIENCY OF ARGININOSUCCINATE SYNTHETASIS USING MRNA
DK3071696T3 (en) 2013-11-22 2019-10-07 Mina Therapeutics Ltd C / EBP ALFA SHORT ACTIVATION RNA COMPOSITIONS AND METHODS OF USE
ES2750661T3 (en) 2014-04-25 2020-03-26 Translate Bio Inc Methods for purification of messenger RNA
CN108096189A (en) * 2016-11-25 2018-06-01 国家纳米科学中心 A kind of elaioplast nanometer particle and its pharmaceutical composition and application
EA201991747A1 (en) 2017-02-27 2020-06-04 Транслейт Био, Инк. NEW CODON-OPTIMIZED CFTR mRNA
US11173190B2 (en) 2017-05-16 2021-11-16 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR
WO2019048631A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Hnf4a sarna compositions and methods of use
WO2019048645A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Stabilized cebpa sarna compositions and methods of use
EP3775211B1 (en) 2018-04-12 2023-04-05 MiNA Therapeutics Limited Sirt1-sarna compositions and methods of use
EP3841208A1 (en) 2018-08-24 2021-06-30 Translate Bio, Inc. Methods for purification of messenger rna
WO2020208361A1 (en) 2019-04-12 2020-10-15 Mina Therapeutics Limited Sirt1-sarna compositions and methods of use
CN110638759A (en) * 2019-10-29 2020-01-03 珠海丽凡达生物技术有限公司 A preparation for in vitro transfection and in vivo mRNA delivery
CA3200234A1 (en) 2020-11-25 2022-06-02 Daryl C. Drummond Lipid nanoparticles for delivery of nucleic acids, and related methods of use
JP2024511092A (en) 2021-03-26 2024-03-12 ミナ セラピューティクス リミテッド TMEM173saRNA composition and method of use
WO2023099884A1 (en) 2021-12-01 2023-06-08 Mina Therapeutics Limited Pax6 sarna compositions and methods of use
WO2023170435A1 (en) 2022-03-07 2023-09-14 Mina Therapeutics Limited Il10 sarna compositions and methods of use
WO2023230587A2 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
WO2024134199A1 (en) 2022-12-22 2024-06-27 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
CA2289702C (en) * 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US20030035829A1 (en) * 1997-07-24 2003-02-20 Townsend And Townsend And Crew Liposomal compositions for the delivery of nucleic acid catalysts
JP5117648B2 (en) * 1999-04-20 2013-01-16 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア Cationic PEG lipids and methods of use.

Also Published As

Publication number Publication date
EP1328254B1 (en) 2007-02-21
DE60126801D1 (en) 2007-04-05
WO2002034236A2 (en) 2002-05-02
ATE354350T1 (en) 2007-03-15
JP2004511572A (en) 2004-04-15
DE60126801T2 (en) 2007-12-06
EP1328254A2 (en) 2003-07-23
CA2426244A1 (en) 2002-05-02
WO2002034236A3 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
AU2002214854A1 (en) Lipid formulations for target delivery
WO2006012502A3 (en) Formulation of insoluble small molecule therapeutics in lipid-based carriers
WO2004064769A3 (en) Methods for making and using topical delivery agents
WO2005120461A3 (en) Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
WO2002058622A3 (en) Sn-38 lipid complexes and methods of use
EP1149115A4 (en) METHODS OF ELICITING BROADLY NEUTRALIZING ANTIBODIES TARGETING HIV-1 gp41
WO2000062813A3 (en) Cationic peg-lipids and methods of use
WO2004090108A3 (en) Irna conjugates
AU2001263106A1 (en) Navigation system, method and software for foot travel
WO2001082932A3 (en) Methods and compositions for enhancing cellular function through protection of tissue components
WO2003077861A3 (en) Water-based delivery systems
WO2004091578A3 (en) Novel encochleation methods, cochleates and methods of use
WO2006013369A3 (en) Compositions forming non-lamellar dispersions
PL1643833T3 (en) Agrochemical formulations
WO2003000233A3 (en) Delivery of small hydrophilic molecules packaged into lipid vesicles
BR0105457A (en) Therapeutic combinations to stimulate bone growth
WO2009141450A3 (en) Liposomes for drug delivery and methods for preparation thereof
WO2004067063A3 (en) Improved formulations for transmucosal vaginal delivery of bisphosphonates
WO2002015959A3 (en) Compounds and compositions for delivering active agents
CA2483916A1 (en) Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs
BR0112258A (en) Poorly Water Soluble Drug Delivery System
WO2003035032A3 (en) New non-phospholipid lipid vesicles (nplv) and their use in cosmetic, therapeutic and prophylactic applications
WO2002072105A3 (en) Improved prostanoid therapies for the treatment of glaucoma
WO2008008827A3 (en) Methods and formulations for optimal local delivery of cell therapy via minimally invasive procedures
AU2072501A (en) Method for promoting lister anonymity during an on-line auction